Follicular Lymphoma Clinical Trials in Rochester, Minnesota

4 studies are recruiting for follicular lymphoma in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

    Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic Rochester, Rochester, Minnesota
    Locations
    115 in total
    Run by
    BeOne Medicines

    See if you can join NCT05006716 on ClinicalTrials.gov

  2. A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

    The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic - Rochester, Rochester, Minnesota
    Locations
    46 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07226843 on ClinicalTrials.gov

  3. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

    Stage
    Phase 1
    Ages
    13 to 90
    Site
    Mayo Clinic, Clinical Trials Referral Office, Rochester, Minnesota
    Locations
    11 in total
    Run by
    Vironexis Biotherapeutics Inc.

    See if you can join NCT06533579 on ClinicalTrials.gov

  4. A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

    The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mayo Clinic, Rochester, Minnesota
    Locations
    12 in total
    Run by
    Enterome

    See if you can join NCT04669171 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.